These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 18473860)
61. Downregulation of p21(WAF1/CIP1) and estrogen receptor alpha in MCF-7 cells by antisense oligonucleotides containing locked nucleic acid (LNA). Jepsen JS; Pfundheller HM; Lykkesfeldt AE Oligonucleotides; 2004; 14(2):147-56. PubMed ID: 15294077 [TBL] [Abstract][Full Text] [Related]
62. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions. MacLeod AR; Crooke ST J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648 [TBL] [Abstract][Full Text] [Related]
63. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Barata P; Sood AK; Hong DS Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280 [TBL] [Abstract][Full Text] [Related]
64. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Mani S; Goel S; Nesterova M; Martin RM; Grindel JM; Rothenberg ML; Zhang R; Tortora G; Cho-Chung YS Ann N Y Acad Sci; 2003 Dec; 1002():252-62. PubMed ID: 14751840 [TBL] [Abstract][Full Text] [Related]
65. Targeting the Bcl-2 family in cancer therapy. Papadopoulos K Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799 [TBL] [Abstract][Full Text] [Related]
71. Targeted manipulation of apoptosis in cancer treatment. Call JA; Eckhardt SG; Camidge DR Lancet Oncol; 2008 Oct; 9(10):1002-11. PubMed ID: 18760670 [TBL] [Abstract][Full Text] [Related]
72. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Tanioka M; Nokihara H; Yamamoto N; Yamada Y; Yamada K; Goto Y; Fujimoto T; Sekiguchi R; Uenaka K; Callies S; Tamura T Cancer Chemother Pharmacol; 2011 Aug; 68(2):505-11. PubMed ID: 21079959 [TBL] [Abstract][Full Text] [Related]
73. Antisense approach to inflammatory bowel disease: prospects and challenges. Marafini I; Di Fusco D; Calabrese E; Sedda S; Pallone F; Monteleone G Drugs; 2015 May; 75(7):723-30. PubMed ID: 25911184 [TBL] [Abstract][Full Text] [Related]
74. Custom cancer therapies: safe and effective treatments for most or all cancers. Summerton JE Ann N Y Acad Sci; 2003 Dec; 1002():189-96. PubMed ID: 14751835 [TBL] [Abstract][Full Text] [Related]
75. Molecule of the Month. Mipomersem sodium. Drug News Perspect; 2008 Oct; 21(8):464. PubMed ID: 19034352 [No Abstract] [Full Text] [Related]
76. Preclinical and clinical experience of antisense therapy for solid tumors. Webb MS; Zon G Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760 [TBL] [Abstract][Full Text] [Related]
78. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430 [TBL] [Abstract][Full Text] [Related]